Study reshapes view of how a common leukemia begins and could point to new therapeutic strategies targeting a common weakness.

Michael Buck, PhD, professor of biochemistry in the Jacobs School, recently received NIH funding to explore how molecular readers of DNA access and activate seemingly hidden genes.

In a world first, a bespoke gene-editing therapy benefited one child. Now researchers plan to launch a clinical trial of the approach ...

Johns Hopkins University School of Medicine alumnus and former faculty member Hamilton O. Smith, M.D., whose 1978 Nobel Prize-winning discovery of restriction enzymes revolutionized genetic ...